Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cytokine-induced killer cells (Chuan An Biotechnology)
- Development stage
- Unknown
- Lead developer
- Chuan An Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cytokine-induced killer (CIK) cells are an ex vivo expanded population of immune effector cells, characterized by a dual T-cell and natural killer (NK) cell phenotype (predominantly CD3+CD56+). Developed by Chuan An Biotechnology for the treatment of hepatocellular carcinoma (HCC), these cells are generated by culturing a patient's peripheral blood mononuclear cells with interferon-gamma, anti-CD3 antibodies, and interleukin-2. CIK cells exhibit potent, non-major histocompatibility complex (MHC)-restricted cytotoxic activity against tumor cells, primarily mediated through the NKG2D receptor. In clinical applications, they are often used as an adjuvant therapy following local treatments such as transarterial chemoembolization (TACE), percutaneous ethanol injection therapy (PEIT), or radiofrequency ablation (RFA) to target residual disease and reduce the risk of recurrence.
- Other names
- CIK cellsAutologous CIK cellsCytokine-induced killer cells
Beyond the preview
Go deeper on autologous cytokine-induced killer cells (Chuan An Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cytokine-induced killer cells (Chuan An Biotechnology).